Gamage M, Ranawaka R. Optimizing growth in pediatric renal transplant recipients: An update. World J Transplant 2024; 14(4): 95967 [PMID: 39697449 DOI: 10.5500/wjt.v14.i4.95967]
Corresponding Author of This Article
Randula Ranawaka, MBBS, MD, Chief Physician, Professor, Senior Researcher, Department of Paediatrics, Faculty of Medicine, University of Colombo, Kynsey Road, Colombo 0094, Sri Lanka. randula@pdt.cmb.ac.lk
Research Domain of This Article
Transplantation
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Dec 18, 2024; 14(4): 95967 Published online Dec 18, 2024. doi: 10.5500/wjt.v14.i4.95967
Optimizing growth in pediatric renal transplant recipients: An update
Manoji Gamage, Randula Ranawaka
Manoji Gamage, Nutrition Division, Ministry of Health, Colombo 0094, Sri Lanka
Manoji Gamage, Medical Nutrition Unit, National Institute of Nephrology, Dialysis and Transplant, Colombo 0094, Sri Lanka
Randula Ranawaka, Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo 0094, Sri Lanka
Randula Ranawaka, University Paediatric Unit, Lady Ridgeway Hospital for Children, Colombo 0094, Sri Lanka
Author contributions: Ranawaka R and Gamage M performed the literature survey; Ranawaka R and Gamage M wrote the manuscript; Gamage M and Ranawaka R edited the final version of the manuscript. Both authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Randula Ranawaka, MBBS, MD, Chief Physician, Professor, Senior Researcher, Department of Paediatrics, Faculty of Medicine, University of Colombo, Kynsey Road, Colombo 0094, Sri Lanka. randula@pdt.cmb.ac.lk
Received: April 23, 2024 Revised: June 20, 2024 Accepted: July 15, 2024 Published online: December 18, 2024 Processing time: 149 Days and 22.1 Hours
Abstract
Growth retardation is a significant complication observed in pediatric renal transplant recipients, originating from a multifactorial etiology. Factors contributing to growth impairment encompass pre-transplant conditions such as primary kidney disease, malnutrition, quality of care, growth deficits at the time of transplantation, dialysis adequacy, and the use of recombinant human growth hormone. Additionally, elements related to the renal transplant itself, such as living donors, corticosteroid usage, and graft functioning, further compound the challenge. Although renal transplantation is the preferred renal replacement therapy, its impact on achieving final height and normal growth in children remains uncertain. The consequences of growth delay extend beyond the physiological realm, negatively influencing the quality of life and social conditions of pediatric renal transplant recipients, and ultimately affecting their educational and employment outcomes. Despite advancements in graft survival rates, growth retardation remains a formidable clinical concern among children undergoing renal transplantation. Major risk factors for delayed final adult height include young age at transplantation, pre-existing short stature, and the use of specific immunosuppressive drugs, particularly steroids. Effective management of growth retardation necessitates early intervention, commencing even before transplantation. Strategies involving the administration of recombinant growth hormone both pre- and post-transplant, along with protocols aimed at minimizing steroid usage, are important for achieving catch-up growth. This review provides a comprehensive outline of the multifaceted nature of growth retardation in pediatric renal transplant recipients, emphasizing the importance of early and targeted interventions to mitigate its impact on the long-term well-being of these children from birth to adolescence.
Core Tip: Growth retardation is a notable challenge among pediatric kidney transplant recipients. Key risk factors for delayed final adult height include early age at transplantation, pre-existing short stature due to chronic kidney disease and dialysis, and the use of certain immunosuppressive drugs, particularly steroids. To effectively manage growth retardation, early intervention is crucial, ideally beginning before transplantation. Important strategies include administering recombinant growth hormone both before and after the transplant, optimizing nutrition, and employing protocols designed to minimize steroid use. These approaches offer the best chances for achieving catch-up growth in renal transplant recipients.